While the top- and bottom-line numbers for BrightSpring Health Services, Inc. (BTSG) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
BrightSpring Health Services NASDAQ: BTSG reported second-quarter 2026 results that exceeded its baseline expectations, led by growth in its Pharmacy Solutions and Provider Services businesses, while reaffirming confidence in its updated full-year outlook.
BrightSpring Health Services, Inc. (BTSG) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.22 per share a year ago.
BrightSpring Health Services, Inc. (BTSG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does BrightSpring Health Services, Inc. (BTSG) have what it takes to be a top stock pick for momentum investors? Let's find out.
BTSG's specialty, infusion and provider services momentum support growth, but IRA pressures and integration risks may weigh on margins.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
If you are looking for stocks that are well positioned to maintain their recent uptrend, BrightSpring Health Services, Inc. (BTSG) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
BrightSpring, Dycom, StoneX and Orion stand out as buy-worthy stocks, backed by rising cash flows and upward earnings estimate revisions.
Here is how BrightSpring Health Services, Inc. (BTSG) and Bioventus (BVS) have performed compared to their sector so far this year.
Medical stocks like Centene, DaVita and BrightSpring could rally as SpaceX IPO-fueled market optimism lifts broader sector sentiment.
BrightSpring, StoneX, Cimpress and Flexsteel stand out as buy-worthy stocks with rising cash flows and upward earnings estimate revisions.